How personal loss and hope drove Elaine Maynard’s work in clinical trials and patient-centric technologies

Citius Pharma receives FDA approval for immunotherapy targeting rare blood cancer

Halda Therapeutics raises $126M to take 'hold and kill' precision cancer drugs to the clinic

Gilead gains accelerated FDA approval for rare liver disease treatment

FDA lifts hold on BioNTech and MediLink's ADC trial After safety revisions

Breakthrough delivery system could transform Alzheimer’s treatment

First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1

Breaking News: Lecanemab approved in UK but unavailable on NHS

Highlights

array(40) {
  [0]=>
  string(4) "7331"
  ["article_id"]=>
  string(4) "7331"
  [1]=>
  string(98) "Roche’s risdiplam achieves primary endpoint in infant-related spinal muscular atrophy trial"
  ["article_title"]=>
  string(98) "Roche’s risdiplam achieves primary endpoint in infant-related spinal muscular atrophy trial"
  [2]=>
  string(150) "The company has reported positive topline results from the pivotal part 2 of the FIREFISH study, which is assessing risdiplam in infants aged between "
  ["short_description"]=>
  string(150) "The company has reported positive topline results from the pivotal part 2 of the FIREFISH study, which is assessing risdiplam in infants aged between "
  [3]=>
  string(573) "
The company has reported positive topline results from the pivotal part 2 of the FIREFISH study, which is assessing risdiplam in infants aged between one and seven months 
&#nl
The post Roche’s risdiplam achieves primary endpoint in infant-related spinal muscular atrophy trial appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(573) "
The company has reported positive topline results from the pivotal part 2 of the FIREFISH study, which is assessing risdiplam in infants aged between one and seven months 
&#nl
The post Roche’s risdiplam achieves primary endpoint in infant-related spinal muscular atrophy trial appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(85) "https://www.pharmaceutical-business-review.com/news/roches-risdiplam-spinal-muscular/"
  ["blog_url"]=>
  string(85) "https://www.pharmaceutical-business-review.com/news/roches-risdiplam-spinal-muscular/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-01-27 15:17:20"
  ["create_at"]=>
  string(19) "2020-01-27 15:17:20"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Roche’s risdiplam achieves primary endpoint in infant-related spinal muscular atrop

The company has reported positive topline results from the pivotal part 2 of the FIREFISH study, which is assessing r

array(40) {
  [0]=>
  string(4) "7332"
  ["article_id"]=>
  string(4) "7332"
  [1]=>
  string(61) "FDA approves TEPEZZA for the treatment of thyroid eye disease"
  ["article_title"]=>
  string(61) "FDA approves TEPEZZA for the treatment of thyroid eye disease"
  [2]=>
  string(150) "TEPEZZA is the first and only FDA-approved medicine for the treatment of TED, a serious, progressive and vision-threatening rare autoimmune disease th"
  ["short_description"]=>
  string(150) "TEPEZZA is the first and only FDA-approved medicine for the treatment of TED, a serious, progressive and vision-threatening rare autoimmune disease th"
  [3]=>
  string(591) "
TEPEZZA is the first and only FDA-approved medicine for the treatment of TED, a serious, progressive and vision-threatening rare autoimmune disease that is associated with proptosis (eye bulging), 
&#nl
The post FDA approves TEPEZZA for the treatment of thyroid eye disease appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(591) "
TEPEZZA is the first and only FDA-approved medicine for the treatment of TED, a serious, progressive and vision-threatening rare autoimmune disease that is associated with proptosis (eye bulging), 
&#nl
The post FDA approves TEPEZZA for the treatment of thyroid eye disease appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(114) "https://www.pharmaceutical-business-review.com/news/fda-approves-tepezza-for-the-treatment-of-thyroid-eye-disease/"
  ["blog_url"]=>
  string(114) "https://www.pharmaceutical-business-review.com/news/fda-approves-tepezza-for-the-treatment-of-thyroid-eye-disease/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-01-27 15:17:20"
  ["create_at"]=>
  string(19) "2020-01-27 15:17:20"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

FDA approves TEPEZZA for the treatment of thyroid eye disease

TEPEZZA is the first and only FDA-approved medicine for the treatment of TED, a serious, progressive and vision-threa

array(40) {
  [0]=>
  string(4) "7333"
  ["article_id"]=>
  string(4) "7333"
  [1]=>
  string(76) "Calidi Biotherapeutics secures series A investments to advance manufacturing"
  ["article_title"]=>
  string(76) "Calidi Biotherapeutics secures series A investments to advance manufacturing"
  [2]=>
  string(150) "The investment efforts were led by Heehyoung Lee, Ph.D., co-founder and managing partner of LumeBio, advisor to Calidi Biotherapeutics and a fifteen-y"
  ["short_description"]=>
  string(150) "The investment efforts were led by Heehyoung Lee, Ph.D., co-founder and managing partner of LumeBio, advisor to Calidi Biotherapeutics and a fifteen-y"
  [3]=>
  string(622) "
The investment efforts were led by Heehyoung Lee, Ph.D., co-founder and managing partner of LumeBio, advisor to Calidi Biotherapeutics and a fifteen-year veteran in the biopharmaceutical space. Dr. 
&#nl
The post Calidi Biotherapeutics secures series A investments to advance manufacturing appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(622) "
The investment efforts were led by Heehyoung Lee, Ph.D., co-founder and managing partner of LumeBio, advisor to Calidi Biotherapeutics and a fifteen-year veteran in the biopharmaceutical space. Dr. 
&#nl
The post Calidi Biotherapeutics secures series A investments to advance manufacturing appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(129) "https://www.pharmaceutical-business-review.com/news/calidi-biotherapeutics-secures-series-a-investments-to-advance-manufacturing/"
  ["blog_url"]=>
  string(129) "https://www.pharmaceutical-business-review.com/news/calidi-biotherapeutics-secures-series-a-investments-to-advance-manufacturing/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-01-27 15:17:20"
  ["create_at"]=>
  string(19) "2020-01-27 15:17:20"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Calidi Biotherapeutics secures series A investments to advance manufacturing

The investment efforts were led by Heehyoung Lee, Ph.D., co-founder and managing partner of LumeBio, advisor to Calid

array(40) {
  [0]=>
  string(4) "7334"
  ["article_id"]=>
  string(4) "7334"
  [1]=>
  string(80) "Eli Lilly to build $470m pharmaceutical manufacturing facility in North Carolina"
  ["article_title"]=>
  string(80) "Eli Lilly to build $470m pharmaceutical manufacturing facility in North Carolina"
  [2]=>
  string(155) "North Carolina Governor Roy Cooper has also announced that Eli Lilly’s move will also help to create over 460 new jobs in the Durham region. The new"
  ["short_description"]=>
  string(155) "North Carolina Governor Roy Cooper has also announced that Eli Lilly’s move will also help to create over 460 new jobs in the Durham region. The new"
  [3]=>
  string(551) "
North Carolina Governor Roy Cooper has also announced that Eli Lilly’s move will also help to create over 460 new jobs in the Durham region. The new job 
&#nl
The post Eli Lilly to build $470m pharmaceutical manufacturing facility in North Carolina appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(551) "
North Carolina Governor Roy Cooper has also announced that Eli Lilly’s move will also help to create over 460 new jobs in the Durham region. The new job 
&#nl
The post Eli Lilly to build $470m pharmaceutical manufacturing facility in North Carolina appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(92) "https://www.pharmaceutical-business-review.com/news/eli-lilly-pharmaceutical-north-carolina/"
  ["blog_url"]=>
  string(92) "https://www.pharmaceutical-business-review.com/news/eli-lilly-pharmaceutical-north-carolina/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-01-27 15:17:20"
  ["create_at"]=>
  string(19) "2020-01-27 15:17:20"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Eli Lilly to build $470m pharmaceutical manufacturing facility in North Carolina

North Carolina Governor Roy Cooper has also announced that Eli Lilly’s move will also help to create over 460 

array(40) {
  [0]=>
  string(4) "7335"
  ["article_id"]=>
  string(4) "7335"
  [1]=>
  string(72) "US reports first case of novel coronavirus from China-returned traveller"
  ["article_title"]=>
  string(72) "US reports first case of novel coronavirus from China-returned traveller"
  [2]=>
  string(150) "The patient had travelled from Wuhan to Washington. The novel coronavirus infection is believed to have originated at a seafood wholesale market in th"
  ["short_description"]=>
  string(150) "The patient had travelled from Wuhan to Washington. The novel coronavirus infection is believed to have originated at a seafood wholesale market in th"
  [3]=>
  string(546) "
The patient had travelled from Wuhan to Washington. The novel coronavirus infection is believed to have originated at a seafood wholesale market in the Chinese city in Hubei 
&#nl
The post US reports first case of novel coronavirus from China-returned traveller appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(546) "
The patient had travelled from Wuhan to Washington. The novel coronavirus infection is believed to have originated at a seafood wholesale market in the Chinese city in Hubei 
&#nl
The post US reports first case of novel coronavirus from China-returned traveller appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(81) "https://www.pharmaceutical-business-review.com/news/novel-coronavirus-us-patient/"
  ["blog_url"]=>
  string(81) "https://www.pharmaceutical-business-review.com/news/novel-coronavirus-us-patient/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-01-27 15:17:20"
  ["create_at"]=>
  string(19) "2020-01-27 15:17:20"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

US reports first case of novel coronavirus from China-returned traveller

The patient had travelled from Wuhan to Washington. The novel coronavirus infection is believed to have originated at

array(40) {
  [0]=>
  string(4) "7336"
  ["article_id"]=>
  string(4) "7336"
  [1]=>
  string(81) "Novartis’ Mayzent gets EC nod for secondary progressive multiple sclerosis"
  ["article_title"]=>
  string(81) "Novartis’ Mayzent gets EC nod for secondary progressive multiple sclerosis"
  [2]=>
  string(150) "The approval for Mayzent from the European Commission (EC) is for SPMS with active disease, confirmed by relapses or imaging features of inflammatory "
  ["short_description"]=>
  string(150) "The approval for Mayzent from the European Commission (EC) is for SPMS with active disease, confirmed by relapses or imaging features of inflammatory "
  [3]=>
  string(574) "
The approval for Mayzent from the European Commission (EC) is for SPMS with active disease, confirmed by relapses or imaging features of inflammatory activity. The sphingosine 1-phosphate receptor 
&#nl
The post Novartis’ Mayzent gets EC nod for secondary progressive multiple sclerosis appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(574) "
The approval for Mayzent from the European Commission (EC) is for SPMS with active disease, confirmed by relapses or imaging features of inflammatory activity. The sphingosine 1-phosphate receptor 
&#nl
The post Novartis’ Mayzent gets EC nod for secondary progressive multiple sclerosis appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(77) "https://www.pharmaceutical-business-review.com/news/novartis-mayzent-smps-eu/"
  ["blog_url"]=>
  string(77) "https://www.pharmaceutical-business-review.com/news/novartis-mayzent-smps-eu/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-01-27 15:17:20"
  ["create_at"]=>
  string(19) "2020-01-27 15:17:20"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Novartis’ Mayzent gets EC nod for secondary progressive multiple sclerosis

The approval for Mayzent from the European Commission (EC) is for SPMS with active disease, confirmed by relapses or 

array(40) {
  [0]=>
  string(4) "7337"
  ["article_id"]=>
  string(4) "7337"
  [1]=>
  string(77) "Armas Pharmaceuticals adds four generic injectables as first launches of 2020"
  ["article_title"]=>
  string(77) "Armas Pharmaceuticals adds four generic injectables as first launches of 2020"
  [2]=>
  string(150) "Armas Pharmaceuticals Inc. (Armas), has begun the new year with launches of four generic injectables: Caffeine Citrate, Docetaxel, Gemcitabine and Ver"
  ["short_description"]=>
  string(150) "Armas Pharmaceuticals Inc. (Armas), has begun the new year with launches of four generic injectables: Caffeine Citrate, Docetaxel, Gemcitabine and Ver"
  [3]=>
  string(618) "
Armas Pharmaceuticals Inc. (Armas), has begun the new year with launches of four generic injectables: Caffeine Citrate, Docetaxel, Gemcitabine and Verapamil HCI. These products are now a part 
&#nl
The post Armas Pharmaceuticals adds four generic injectables as first launches of 2020 appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(618) "
Armas Pharmaceuticals Inc. (Armas), has begun the new year with launches of four generic injectables: Caffeine Citrate, Docetaxel, Gemcitabine and Verapamil HCI. These products are now a part 
&#nl
The post Armas Pharmaceuticals adds four generic injectables as first launches of 2020 appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(130) "https://www.pharmaceutical-business-review.com/news/armas-pharmaceuticals-adds-four-generic-injectables-as-first-launches-of-2020/"
  ["blog_url"]=>
  string(130) "https://www.pharmaceutical-business-review.com/news/armas-pharmaceuticals-adds-four-generic-injectables-as-first-launches-of-2020/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-01-27 15:17:20"
  ["create_at"]=>
  string(19) "2020-01-27 15:17:20"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Armas Pharmaceuticals adds four generic injectables as first launches of 2020

Armas Pharmaceuticals Inc. (Armas), has begun the new year with launches of four generic injectables: Caffeine Citrat

array(40) {
  [0]=>
  string(4) "7415"
  ["article_id"]=>
  string(4) "7415"
  [1]=>
  string(192) "A2Dominion, BMJ, Carnival, Harrods, John Lewis, Nestle, Pladis, Sanofi Pasteur, The Adecco Group and Three all named Top Engaged Workplaces at the 2019 UK & European Employee Engagement Awards"
  ["article_title"]=>
  string(192) "A2Dominion, BMJ, Carnival, Harrods, John Lewis, Nestle, Pladis, Sanofi Pasteur, The Adecco Group and Three all named Top Engaged Workplaces at the 2019 UK & European Employee Engagement Awards"
  [2]=>
  string(150) "The victorious were announced at a Gala ceremony at Troxy in London last night London – January 24, 2020 – The winners of the 2019 UK &"
  ["short_description"]=>
  string(150) "The victorious were announced at a Gala ceremony at Troxy in London last night London – January 24, 2020 – The winners of the 2019 UK &"
  [3]=>
  string(492) "The victorious were announced at a Gala ceremony at Troxy in London last night London – January 24, 2020 – The winners of the 2019 UK & European Employee Engagement Awards, were announced last night at the gala ceremony at the iconic Troxy. With the blue riband Company of the Year award going to A2Dominion. The Employee Engagement Awards honours those organisations that put workforce engagement at the heart of their business strategy. This years...&#nl&#nlSource: RealWire"
  ["description"]=>
  string(492) "The victorious were announced at a Gala ceremony at Troxy in London last night London – January 24, 2020 – The winners of the 2019 UK & European Employee Engagement Awards, were announced last night at the gala ceremony at the iconic Troxy. With the blue riband Company of the Year award going to A2Dominion. The Employee Engagement Awards honours those organisations that put workforce engagement at the heart of their business strategy. This years...&#nl&#nlSource: RealWire"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "4"
  ["category"]=>
  string(1) "4"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "65"
  ["rss_id"]=>
  string(2) "65"
  [14]=>
  string(107) "http://www.realwire.com/releases/Top-Engaged-Workplaces-at-the-2019-UK--European-Employee-Engagement-Awards"
  ["blog_url"]=>
  string(107) "http://www.realwire.com/releases/Top-Engaged-Workplaces-at-the-2019-UK--European-Employee-Engagement-Awards"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-01-27 15:17:50"
  ["create_at"]=>
  string(19) "2020-01-27 15:17:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

A2Dominion, BMJ, Carnival, Harrods, John Lewis, Nestle, Pladis, Sanofi Pasteur, The Adecco

The victorious were announced at a Gala ceremony at Troxy in London last night London – January 24, 2020 – T

array(40) {
  [0]=>
  string(4) "7620"
  ["article_id"]=>
  string(4) "7620"
  [1]=>
  string(75) "Opdivo delivers superior five-year survival results in renal cell carcinoma"
  ["article_title"]=>
  string(75) "Opdivo delivers superior five-year survival results in renal cell carcinoma"
  [2]=>
  string(150) "The company said that 26% of patients with previously treated advanced or metastatic renal cell carcinoma are alive at five years of treatment with Op"
  ["short_description"]=>
  string(150) "The company said that 26% of patients with previously treated advanced or metastatic renal cell carcinoma are alive at five years of treatment with Op"
  [3]=>
  string(556) "
The company said that 26% of patients with previously treated advanced or metastatic renal cell carcinoma are alive at five years of treatment with Opdivo. According to Bristol-Myers 
&#nl
The post Opdivo delivers superior five-year survival results in renal cell carcinoma appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(556) "
The company said that 26% of patients with previously treated advanced or metastatic renal cell carcinoma are alive at five years of treatment with Opdivo. According to Bristol-Myers 
&#nl
The post Opdivo delivers superior five-year survival results in renal cell carcinoma appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(79) "https://www.pharmaceutical-business-review.com/news/opdivo-checkmate-025-study/"
  ["blog_url"]=>
  string(79) "https://www.pharmaceutical-business-review.com/news/opdivo-checkmate-025-study/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-02-18 11:37:47"
  ["create_at"]=>
  string(19) "2020-02-18 11:37:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Opdivo delivers superior five-year survival results in renal cell carcinoma

The company said that 26% of patients with previously treated advanced or metastatic renal cell carcinoma are alive a

array(40) {
  [0]=>
  string(4) "7621"
  ["article_id"]=>
  string(4) "7621"
  [1]=>
  string(158) "Celltrion showcases positive one-year results for subcutaneous formulation of infliximab in patients with active Crohn’s disease and ulcerative colitis"
  ["article_title"]=>
  string(158) "Celltrion showcases positive one-year results for subcutaneous formulation of infliximab in patients with active Crohn’s disease and ulcerative colitis"
  [2]=>
  string(150) "Results presented at The European Crohn’s and Colitis Organisation (ECCO) 2020 annual congress in Vienna, Austria demonstrated that the SC formu"
  ["short_description"]=>
  string(150) "Results presented at The European Crohn’s and Colitis Organisation (ECCO) 2020 annual congress in Vienna, Austria demonstrated that the SC formu"
  [3]=>
  string(772) "
Results presented at The European Crohn’s and Colitis Organisation (ECCO) 2020 annual congress in Vienna, Austria demonstrated that the SC formulation of CT-P13 was comparable to the IV 
&#nl
The post Celltrion showcases positive one-year results for subcutaneous formulation of infliximab in patients with active Crohn’s disease and ulcerative colitis appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(772) "
Results presented at The European Crohn’s and Colitis Organisation (ECCO) 2020 annual congress in Vienna, Austria demonstrated that the SC formulation of CT-P13 was comparable to the IV 
&#nl
The post Celltrion showcases positive one-year results for subcutaneous formulation of infliximab in patients with active Crohn’s disease and ulcerative colitis appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(203) "https://www.pharmaceutical-business-review.com/news/celltrion-showcases-positive-one-year-results-for-subcutaneous-formulation-of-infliximab-in-patients-with-active-crohns-disease-and-ulcerative-colitis/"
  ["blog_url"]=>
  string(203) "https://www.pharmaceutical-business-review.com/news/celltrion-showcases-positive-one-year-results-for-subcutaneous-formulation-of-infliximab-in-patients-with-active-crohns-disease-and-ulcerative-colitis/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-02-18 11:37:47"
  ["create_at"]=>
  string(19) "2020-02-18 11:37:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Celltrion showcases positive one-year results for subcutaneous formulation of infliximab i

Results presented at The European Crohn’s and Colitis Organisation (ECCO) 2020 annual congress in Vienna, Austr

array(40) {
  [0]=>
  string(4) "7622"
  ["article_id"]=>
  string(4) "7622"
  [1]=>
  string(181) "New phase 3b interim data from STARDUST study show majority patients with moderately to severely active Crohn’s Disease achieved clinical remission after two doses of STELARA"
  ["article_title"]=>
  string(181) "New phase 3b interim data from STARDUST study show majority patients with moderately to severely active Crohn’s Disease achieved clinical remission after two doses of STELARA"
  [2]=>
  string(150) "Intestinal ultrasound (IUS) responses were assessed and were detected as early as week 4.2 Week 16 data (digital oral presentation or DOP 13) and IUS "
  ["short_description"]=>
  string(150) "Intestinal ultrasound (IUS) responses were assessed and were detected as early as week 4.2 Week 16 data (digital oral presentation or DOP 13) and IUS "
  [3]=>
  string(795) "
Intestinal ultrasound (IUS) responses were assessed and were detected as early as week 4.2 Week 16 data (digital oral presentation or DOP 13) and IUS response data (DOP 
&#nl
The post New phase 3b interim data from STARDUST study show majority patients with moderately to severely active Crohn’s Disease achieved clinical remission after two doses of STELARA appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(795) "
Intestinal ultrasound (IUS) responses were assessed and were detected as early as week 4.2 Week 16 data (digital oral presentation or DOP 13) and IUS response data (DOP 
&#nl
The post New phase 3b interim data from STARDUST study show majority patients with moderately to severely active Crohn’s Disease achieved clinical remission after two doses of STELARA appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(226) "https://www.pharmaceutical-business-review.com/news/new-phase-3b-interim-data-from-stardust-study-show-majority-patients-with-moderately-to-severely-active-crohns-disease-achieved-clinical-remission-after-two-doses-of-stelara/"
  ["blog_url"]=>
  string(226) "https://www.pharmaceutical-business-review.com/news/new-phase-3b-interim-data-from-stardust-study-show-majority-patients-with-moderately-to-severely-active-crohns-disease-achieved-clinical-remission-after-two-doses-of-stelara/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-02-18 11:37:47"
  ["create_at"]=>
  string(19) "2020-02-18 11:37:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

New phase 3b interim data from STARDUST study show majority patients with moderately to se

Intestinal ultrasound (IUS) responses were assessed and were detected as early as week 4.2 Week 16 data (digital oral

array(40) {
  [0]=>
  string(4) "7623"
  ["article_id"]=>
  string(4) "7623"
  [1]=>
  string(80) "Epizyme seeks FDA accelerated approval for Tazverik to treat follicular lymphoma"
  ["article_title"]=>
  string(80) "Epizyme seeks FDA accelerated approval for Tazverik to treat follicular lymphoma"
  [2]=>
  string(155) "The regulator has accepted the firm’s new drug application (NDA) for the accelerated approval of tazemetostat to treat patients with relapsed or ref"
  ["short_description"]=>
  string(155) "The regulator has accepted the firm’s new drug application (NDA) for the accelerated approval of tazemetostat to treat patients with relapsed or ref"
  [3]=>
  string(618) "
The regulator has accepted the firm’s new drug application (NDA) for the accelerated approval of tazemetostat to treat patients with relapsed or refractory FL who have secured at 
&#nl
The post Epizyme seeks FDA accelerated approval for Tazverik to treat follicular lymphoma appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(618) "
The regulator has accepted the firm’s new drug application (NDA) for the accelerated approval of tazemetostat to treat patients with relapsed or refractory FL who have secured at 
&#nl
The post Epizyme seeks FDA accelerated approval for Tazverik to treat follicular lymphoma appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(133) "https://www.pharmaceutical-business-review.com/news/epizyme-seeks-fda-accelerated-approval-for-tazverik-to-treat-follicular-lymphoma/"
  ["blog_url"]=>
  string(133) "https://www.pharmaceutical-business-review.com/news/epizyme-seeks-fda-accelerated-approval-for-tazverik-to-treat-follicular-lymphoma/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-02-18 11:37:47"
  ["create_at"]=>
  string(19) "2020-02-18 11:37:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Epizyme seeks FDA accelerated approval for Tazverik to treat follicular lymphoma

The regulator has accepted the firm’s new drug application (NDA) for the accelerated approval of tazemetostat